Wall Street Archives - Page 2 of 5

J&J keeps vaccine sales outlook unchanged after third-quarter 2021 miss

Business, COVID-19 Vaccines, Forecasts, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Medical Devices, Quarterly results, Shares, Wall Street Estimates

Johnson & Johnson on Oct. 19 reported lower-than-expected quarterly revenue after sales of the company’s Covid-19 vaccine missed Wall Street estimates following a string of production setbacks.

October 19, 2021/by Andrew Humphreys

Bristol Myers sees return to growth for Opdivo, tops estimates

Advanced lung cancer, Blockbusters, Bristol Myers Squibb, Business, Coronavirus Disease (COVID-19) Pandemic, Quarterly results, Therapeutics, Wall Street Estimates

Bristol Myers Squibb Co. reported second-quarter 2021 earnings that topped Wall Street estimates, as sales of the company’s flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter.

July 28, 2021/by Andrew Humphreys

U.S. Covid-19 cases rising, mostly among unvaccinated – officials

CDC, COVID-19 cases, Covid-19 Data, COVID-19 Deaths, Delta Variant (B.1.617.2; India), Health Officials, Hospitalized COVID-19 Patients, United States, Wall Street, White House

U.S. Covid-19 cases are up around 11 percent over the previous week – almost entirely among people who have not been vaccinated – officials said on July 8, as the highly infectious Delta variant becomes the dominant Covid-19 strain in the country.

July 8, 2021/by Andrew Humphreys

J&J’s Covid-19 vaccine shows promise against Delta variant

Clinical Data, COVID-19 Vaccines, Covid-19 Variants, Delta Variant (B.1.617.2; India), Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Wall Street Analysts, World Health Organization

Johnson & Johnson said the company’s single-shot Covid-19 vaccine showed promise against the highly contagious Delta variant in a laboratory study.

July 2, 2021/by Andrew Humphreys

Amgen issues 2021 outlook below Street view, shares dip

Amgen, Biotechnology Companies, Blockbusters, Business, Cancer, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Forecasts, Quarterly results, R&D, Shares, Wall Street Analysts

U.S. biotech Amgen Inc. provided a 2021 earnings forecast below Wall Street estimates and said the company paused or halted enrollment for clinical trials of three cancer drugs.

February 2, 2021/by Andrew Humphreys

Biogen plunges 30% after FDA panel votes against Alzheimer’s drug

Advisory Panels, Alzheimer’s disease, Business, FDA, Potential Blockbusters, Shares, Wall Street Analysts

Biogen Inc.’s shares slumped as the drugmaker’s chances of getting a regulatory approval for the experimental Alzheimer’s treatment aducanumab suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.

November 9, 2020/by Andrew Humphreys

Biogen Alzheimer’s drug closer to approval with U.S. FDA staff backing, shares jump 40%

Alzheimer’s disease, Analysis, Business, Clinical Data, FDA, Partnerships, Patents, Potential Blockbusters, Shares, Wall Street Analysts

Biogen Inc. showed “exceptionally persuasive” evidence that the company’s experimental Alzheimer’s disease drug aducanumab is effective, U.S. Food and Drug Administration staff said, elevating chances of a swift approval and sending company shares soaring.

November 4, 2020/by Andrew Humphreys

Gilead cuts 2020 sales outlook as Covid-19 drug remdesivir falls short

Analysis, Antivirals, Blockbusters, Business, COVID-19 cases, Covid-19 Drugs, Forecasts, Remdesivir, Sales, Shares, Therapeutics, Wall Street Estimates

Gilead Sciences Inc. cut the company’s 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with Covid-19.

October 29, 2020/by Andrew Humphreys

Biogen submits U.S. marketing application for Alzheimer’s disease drug

Alzheimer's, Blockbusters, Business, FDA, FDA/Regulatory, New Drug Application Submission, Patents, Potential Blockbusters, Shares, Stocks, Wall Street Analysts

Biogen announced the widely awaited submission of a U.S. marketing application for the experimental Alzheimer’s therapy aducanumab, sending the company’s shares up more than 8 percent before the bell.

July 8, 2020/by Reuters Health